ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026. Details of the even ...

Partnership with leading nuclear medicine specialist enables advancing pipeline of wholly-owned Radio-DARPin therapeutics for imaging and therapeutic radio-isotopes, including Actinium-225 (225Ac)ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it has en ...

Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information  February 26, 2026, 6:30 AM CET    Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives o ...

Core Viewpoint - Vir Biotechnology, Inc. has announced the pricing of its public offering of common stock, aiming to raise $150 million through the sale of 17,647,058 shares at $8.50 per share, with a potential additional option for underwriters to purchase up to 2,647,058 shares [1] Group 1: Offering Details - The public offering consists of 17,647,058 shares priced at $8.50 each, expected to generate gross proceeds of $150 million before expenses [1] - Underwriters have a 30-day option to purchase an additional 2,647,058 shares at the public offering price [1] - The offering is set to close on February 27, 2026, pending customary closing conditions [1] Group 2: Underwriters and Registration - Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering [1] - The shares are being offered under an automatically effective shelf registration statement filed with the SEC on November 3, 2023 [1] Group 3: Company Overview - Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer [1] - The company's clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers targeting solid tumors [1]

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $100 million, before deducting underwriting discounts and commissions ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth emerged [6].

The trading activity of members of Congress is closely monitored and investors are looking to see which Magnificent Seven stocks are most loved and which large-cap names are being bought and sold. When it comes to a member of Congress buying up shares of small-cap stocks, investors may pay even closer attention. • Genprex stock is among today’s weakest performers. What’s behind GNPX decline?Congressman Buys Small-Cap Stocks AgainCongressman Tim Moore (R-N.C.) made multiple trades in 2025, including buying s ...

Arcus Biosciences (NYSE:RCUS) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBob Goeltz - CFODaniel Bronder - Equity Research AssociateHolli Kolkey - VP of Corporate AffairsJen Jarret - COOJonathan Miller - Managing DirectorJuan Jaen - President and Co-FounderRichard Marcus - CMOSalim Syed - Managing DirectorTerry Rosen - CEOYigal Nochomovitz - Director, Biotech Equity ResearchConference Call ParticipantsEmily Bodnar - Biotech Equity Research AnalystNone - AnalystNone - AnalystNone ...

Sarepta Therapeutics (NasdaqGS:SRPT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBrian Abrahams - Managing Director and Co-Head of Biotechnology Equity ResearchDoug Ingram - President and Chief Executive OfficerIan M. Estepan - VP of Investor RelationsLouise Rodino-Klapac - Executive VP, Chief Scientific Officer, and Head of Research and DevelopmentMichael Yee - Global Head of Biotechnology Equity ResearchPatrick Moss - Executive VP and Chief Commercial OfficerRyan Wong - Interim ...

Arcutis Biotherapeutics (NasdaqGS:ARQT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBrian Schoelpkopf - VP of Investor RelationsDouglas Tsao - Managing DirectorFrank Watanabe - President and CEOIkenna Okafor - Biotechnology Equity ResearchLata Vyravan - CFOPatrick Burnett - CMORitch Law - VP in Global Investment ResearchSeamus Fernandez - Senior Managing DirectorSerge Belanger - Managing DirectorTodd Edwards - CCOConference Call ParticipantsJudah Frommer - Executive Director, Sen ...